Medicus Pharma Reports Strong Phase 2 Results for Skinject in Skin Cancer Treatment

Medicus Pharma (NASDAQ: MDCX) is reporting strong progress in its clinical pipeline, with new data supporting its Skinject microneedle technology for treating basal cell carcinoma. The Phase 2 study demonstrated clinical clearance rates up to 73%, with overall response rates around 80%, highlighting the potential of a noninvasive, patient-friendly alternative to surgery. With encouraging results and validation from key opinion leaders, Medicus is preparing for FDA discussions and potential strategic partnerships as it advances toward the next stage of development. #MedicusPharma #MDCX #Biotech #SkinCancer #BasalCellCarcinoma #ClinicalTrials #DrugDevelopment #HealthcareInnovation #MedicalResearch #Oncology #Microneedle #Pharmaceuticals #BiotechInvesting #AnnaBerry #NewsOut